Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases

Zeitschrift fur Rheumatologie

Volumn 62, Issue 2, 2003, Pages 155-160

  Ujfalussy, I ^a   Koo E ^a   Sesztak M ^b   Gergely, P ^c  

^a Polyclin Hospitaller Bros St J   (Hungary)

^b NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Disease modifying antirheumatic drugs; Life table analysis; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; CHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PROTOCOL; CONFERENCE PAPER; DERMATITIS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD; PROTEINURIA; PSORIATIC ARTHRITIS; RASH; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GOLD SODIUM THIOMALATE; HUMANS; LIFE TABLES; LONG-TERM CARE; MALE; METHOTREXATE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0038246439     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-003-0458-2     Document Type: Conference Paper

References (29)

1. Almeyda J, Barnardo D, Baer H et al (1972) Structural and functional abnormalities of the liver in psoriasis before and during methotrexate therapy. Br J Dermatol 87:623-631
2. Capell HA, Maiden N, Madhok R, Hampson R, Thomson EA (1998) Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. J Rheumatol 25:1880-1886
3. Danning CL, Boumpasd DT (1998) Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: an update on mechanism of action. Clin Exp Rheumatol 16:595-604
4. Derwart BB, Gall EP, Schumacher HR et al (1978) Chrysotherapy in psoriatic arthritis: efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum 21:513-515
5. Drosos AA, Tsifetaki N, Tsiakou EK et al (1997) Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol 15:263-267
6. Dougados M, Linden S, Leirisalo-Repo M (1995) Sulfasalazine in the treatment of spondylarthropathy: a randomized multicentre, double-blind placebo-controlled study. Arthritis Rheum 38:618-627
7. Egsmose C, Lund B, Borg G et al (1995) Patients with rheumatoid arthritis benefit form early second line therapy: 5 year follow up of a prospective double blind placebo controlled study. J Rheumatol 22:2208-2213
8. Espinosa LR, Zakraoui L, Espinosa CG et al (1992) Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 19:872-877
9. Farr M, Kitas GD, Waterhouse L et al (1990) Sulfasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 29:46-49
10. Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. Arthritis Rheum 35:1117-1125
11. Fraser SM, Hopkins R, Hunter JA, Nerumann V, Capell HA, Bird HA (1993) Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 32:923-925
12. Fries JF, Williams CA, Ramey D, Bloch DA (1993) The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36:297-306
13. Gladman DD (1992) Psoriatic arthritis: recent advances in pathogenesis and treatment. Rheum Dis Clin North Am 18:246-256
14. Gladman DD (1993) Toward unravelling the mystery of psoriatic arthritis. Arthritis Rheum 36:881-884
15. Gomez-Vaquero C, Rodrigez-Moreno J, Ros S, Marcos R, Fiter J, Roig-Escofet D (1996) Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Br J Rheumatol 35:564-567
16. Goupille P, Valat JP (1996) Sulfasalazine: a definitively efficient treatment for psoriatic arthritis J Rheumatol 23:791 (letter)
17. Gupta AK, Grober JS, Hamilton TA et al (1995) Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. Br J Rheumatol 22:894-898
18. Jones G, Crotty M, Brooks P, and the psoriatic arthritis meta-analysis study group (1997) Psoriatic arthritis: a quantitative overview of therapeutic options. Br J Rheumatol 36:95-99
19. Lacaille D, Stein HB, Raboud J, Klinkhoff AV (2000) Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate. J Rheumatol 27:1922-1927
20. McCarty DJ, Harman JG, Grassanovich JL, Qian C, Klein JP (1995) Combination drug therapy of seropositive rheumatoid arthritis. J Rheumatol 22:1636-1645
21. Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R (1998) A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 37:1060-1068
22. O'Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquire, or a combination of all three medications. N Engl J Med 334:1287-1291
23. Palit J, Hill J, Capell HA, Carey J et al (1990) A multicentre double-blind comparison of auranofin intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 29:280-283
24. Rau R, Herborn H, Menninger H, Blechschmidt J (1997) Comparison of intramuscular gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 36:345-352
25. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G (1998) The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 25:1957-1961
26. van Riel PLCM, van Gestel AM, van de Putte LBA (1995) Long-term usage and side-effect profile of sulfasalazine in rheumatoid arthritis. Br J Rheumatol 34(Suppl):40-42
27. Ujfalussy I, Koó É, Seszták M (2001) Termination of disease modifying antirheumatic drugs in psoriatic arthritis J Rheumatol 28:882 (letter)
28. Weinblatt ME, Kaplan H, Germain BF et al (1994) Methotrexate in rheumatoid arthritis. Arthritis Rheum 38: 1492-1498
29. Wolfe F, Hawley DJ, Cathey MA (1990) Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17:994-1002.